MyFinsight
Home
Blog
About
Proceeds from purchases
of common stock in...
$4,265,275
(-33.27%↓ Y/Y)
Net cash provided by
financing activities
$4,168,375
(15.31%↑ Y/Y)
Canceled cashflow
$96,900
Net increase
(decrease) in cash
$2,226,177
(713.30%↑ Y/Y)
Canceled cashflow
$1,942,198
Principal payments of
notes payable
$96,802
(-93.70%↓ Y/Y)
Cash in lieu of shares
$98
(-89.42%↓ Y/Y)
Loss on impairment of
goodwill
$486,000
(-95.78%↓ Y/Y)
Accounts payable
$312,116
(214.41%↑ Y/Y)
Change in fair value of
series d derivative...
$136,471
Prepaid expenses and
other current assets
-$67,603
(66.43%↑ Y/Y)
Accounts receivable
-$41,450
(-164.27%↓ Y/Y)
Stock-based compensation
$7,359
(-87.78%↓ Y/Y)
Depreciation and
amortization
$2,632
(-68.84%↓ Y/Y)
Change in fair value of
contingent warrant...
-$400
(96.01%↑ Y/Y)
Net cash used in
operating activities
-$1,918,067
(43.75%↑ Y/Y)
Effect of exchange rate
changes on cash
-$24,131
(95.75%↑ Y/Y)
Canceled cashflow
$1,054,031
Net loss
-$2,867,303
(73.74%↑ Y/Y)
Inventories
$76,247
(4.79%↑ Y/Y)
Accrued expenses
-$28,548
(-186.86%↓ Y/Y)
Back
Back
Cash Flow
Onconetix, Inc. (ONCO)
Onconetix, Inc. (ONCO)
source: myfinsight.com